Haemonetics Corporation (NYSE:HAE – Free Report) – Equities research analysts at Zacks Research lowered their Q2 2027 earnings estimates for shares of Haemonetics in a research report issued to clients and investors on Tuesday, August 25th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of $1.30 per share for the quarter, down from their prior forecast of $1.32. The consensus estimate for Haemonetics’ current full-year earnings is $5.28 per share. Zacks Research also issued estimates for Haemonetics’ Q3 2027 earnings at $1.36 EPS, Q4 2027 earnings at $1.46 EPS, FY2027 earnings at $5.27 EPS, Q1 2028 earnings at $1.27 EPS, Q2 2028 earnings at $1.44 EPS, Q3 2028 earnings at $1.50 EPS, Q4 2028 earnings at $1.46 EPS, FY2028 earnings at $5.67 EPS, Q1 2029 earnings at $1.41 EPS and FY2029 earnings at $6.20 EPS.
HAE has been the topic of a number of other reports. Citigroup upped their price target on Haemonetics from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Friday, August 7th. BTIG Research lifted their price objective on Haemonetics from $96.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Weiss Ratings raised Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. Bank of America upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and upped their target price for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Finally, Mizuho raised their price target on shares of Haemonetics from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $97.56.
Haemonetics Stock Down 0.0%
Haemonetics stock opened at $108.35 on Wednesday. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of 53.11, a PEG ratio of 2.17 and a beta of 0.52. The stock has a fifty day simple moving average of $83.00 and a two-hundred day simple moving average of $69.11. Haemonetics has a 12 month low of $47.31 and a 12 month high of $109.57. The company has a current ratio of 3.08, a quick ratio of 1.91 and a debt-to-equity ratio of 1.40.
Haemonetics (NYSE:HAE – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. Haemonetics had a return on equity of 27.55% and a net margin of 7.12%.The business had revenue of $339.38 million for the quarter, compared to analysts’ expectations of $327.86 million. During the same period in the prior year, the firm posted $1.10 EPS. The firm’s quarterly revenue was up 5.5% on a year-over-year basis.
Hedge Funds Weigh In On Haemonetics
Several hedge funds and other institutional investors have recently modified their holdings of the company. Kemnay Advisory Services Inc. purchased a new position in shares of Haemonetics in the 4th quarter worth $26,000. Leonteq Securities AG purchased a new stake in Haemonetics during the fourth quarter valued at $30,000. EverSource Wealth Advisors LLC increased its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares during the last quarter. Kestra Advisory Services LLC bought a new position in Haemonetics in the fourth quarter valued at about $34,000. Finally, Kelleher Financial Advisors bought a new position in Haemonetics in the second quarter valued at about $38,000. 99.67% of the stock is owned by institutional investors.
Trending Headlines about Haemonetics
Here are the key news stories impacting Haemonetics this week:
- Positive Sentiment: Zacks raised its FY2027 EPS forecast to $5.27 from $5.20, lifted Q4 2027 EPS to $1.46 from $1.42, increased Q1 2029 EPS to $1.41 from $1.33, and nudged FY2029 EPS to $6.20 from $6.19. These upgrades suggest improving expectations for Haemonetics’ longer-term earnings growth.
- Neutral Sentiment: The revisions are relatively small and apply primarily to periods two or more years ahead. Zacks continues to project FY2028 EPS of $5.67 and FY2029 EPS of $6.20, indicating an earnings-growth trajectory but limited near-term change to the broader outlook.
- Negative Sentiment: Zacks reduced estimates for Q2 2027 EPS to $1.30 from $1.32, Q3 2027 EPS to $1.36 from $1.37, Q1 2028 EPS to $1.27 from $1.31, Q2 2028 EPS to $1.44 from $1.45, Q3 2028 EPS to $1.50 from $1.52, and FY2028 EPS to $5.67 from $5.69. The cuts point to some pressure on intermediate-term earnings expectations.
Haemonetics Company Profile
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
Read More
- Five stocks we like better than Haemonetics
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
